Panulisib

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206131

CAS#: 1356033-60-7

Description: Panulisib, also known as P7170 and AK151761, is a small molecule inhibitor of PI3K (IC50 = 2.2 nM) and mTOR (IC50 = 4.4 nM). It also inhibits ALK1 and DNA-PK, two important enzymes involved in angiogenesis and DNA repair with IC50 of 47 and 1.5 nM, respectively. P7170 inhibited PI3K-mTOR pathway proteins pAKT, pS6 and p4EBP1 by 90 to 100 % in Kras mutated NSCLC cell line (H460) in a western blot assay. P7170 also exhibited potent cytotoxicity activity against two Kras mutated NSCLC (H460 and A549) cell lines with IC50 values of 7 and 5 nM. P7170 by virtue of its unique profile represents an opportunity to deliver a first-in-class therapeutic option for patients saddled with Kras mutated non small cell lung cancer.


Chemical Structure

img
Panulisib
CAS# 1356033-60-7

Theoretical Analysis

MedKoo Cat#: 206131
Name: Panulisib
CAS#: 1356033-60-7
Chemical Formula: C27H20F3N9
Exact Mass: 527.17938
Molecular Weight: 527.50321
Elemental Analysis: C, 61.48; H, 3.82; F, 10.80; N, 23.90

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Synonym: AK151761; AK 151761; AK-151761; P7170; P 7170; P-7170; Panulisib.

IUPAC/Chemical Name: (E)-N-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1-(6-(2-cyanopropan-2-yl)pyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-ylidene)cyanamide

InChi Key: VJLRLTSXTLICIR-AUGOTPMTSA-N

InChi Code: InChI=1S/C27H20F3N9/c1-26(2,13-31)22-7-5-17(11-35-22)39-23-18-8-15(16-9-19(27(28,29)30)24(33)36-10-16)4-6-20(18)34-12-21(23)38(3)25(39)37-14-32/h4-12H,1-3H3,(H2,33,36)/b37-25+

SMILES Code: N#C/N=C(N1C2=CC=C(C(C)(C#N)C)N=C2)\N(C)C3=C1C4=CC(C5=CC(C(F)(F)F)=C(N)N=C5)=CC=C4N=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 527.50321 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1. Kumar, Sanjay; Sharma, Rajiv; Zahler, Robert; Sahu, Bichismita; Agarwal, Veena R.; Naik, Nishigandha. Preparation of substituted imidazoquinoline derivatives as phosphatidylinositol-​3-​kinase inhibitors. PCT Int. Appl. (2012), WO 2012007926 A1 20120119.

2: Jalota-Badhwar A, Bhatia DR, Boreddy S, Joshi A, Venkatraman M, Desai N, Chaudhari S, Bose J, Kolla LS, Deore V, Yewalkar N, Kumar S, Sharma R, Damre A, More A, Sharma S, Agarwal VR. P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity. Mol Cancer Ther. 2015 May;14(5):1095-106. doi: 10.1158/1535-7163.MCT-14-0486. Epub 2015 Feb 19. PubMed PMID: 25700704.

3: Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW. The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10. PubMed PMID: 25491778; PubMed Central PMCID: PMC4302040.

4: Venkatesha VA, Joshi A, Venkataraman M, Sonawane V, Bhatia D, Tannu P, Bose J, Choudhari S, Srivastava A, Pandey PK, Lad VJ, Sangana R, Ahmed T, Damre A, Deore V, Sahu B, Kumar S, Sharma S, Agarwal VR. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer. Mol Cancer. 2014 Dec 2;13:259. doi: 10.1186/1476-4598-13-259. PubMed PMID: 25466244; PubMed Central PMCID: PMC4289333.

5. Frederick W. Goldberg,*a Paula Daunt,b Stuart E. Pearson,a Ryan Greenwood,a Matthew Gristb and Judit É. Debreczenib Identification and optimisation of a series of N-(4-anilino-2-pyridyl)acetamide activin receptor-like kinase 1 (ALK1) inhibitors. Med. Chem. Commun., 2016,7, 1204-1208

Panulisib

10.0mg / Not available


Additional Information

   Note: Structure was from http://mct.aacrjournals.org/content/14/5/1095. Med. Chem. Commun., 2016,7, 1204-1208